Member Info for chester18

As Yoda says, "Patience you must have my young Padawan". Patience is the ability to accept delay without Stress or Anxiety.. To have trust that all will be well and that your judgement will ultimately be proven correct. There can be no quick fix when proving a new drug or technology that impacts on a person's health or well-being. I for my part trust that Scancell's technology will succeed, all in good time. All the best, Chester

Thank you Nomlungu. DCell is a patented system that provides new and a much better way to treat wounds and skin damage. It's not competing with anything, its a disruptive product. Once used by a hospital or a surgeon and they see the clinical and cost benefits, DCell is what they want to use. The current growth and projected growth both point to this being the case. My question about possible MCap is really asking what we can expect the price to be once we hit say £40M turnover and actually make £5 or 6M a year. What could we expect the multiple to be?

The projected turnover for the next 3 years are : 2018 £11.3 M 2019 £18.4 M 2020 £25.4 M at which point profits will be greater than operational costs. So presuming we move into yearly profits what would we expect the MCap to be. Can anyone hazard a guess?

These are exciting times for Tissue Regenix. Sales contracts in place with further deals to be struck, production facilities increased to meet the projected demand and more products to be added over the coming months. The only reason the price is 8.5p and not18.5p is that we have to scale up the business and for some reason the market is being cautious. They keep on achieving their sales targets and turnover targets so I'm unsure why there is so much doubt. My take on this is, accumulate and hold, profitability is not that far away. Does anyone have any ideas of where the share price will be once we start generating operational profits? ATB Chester....

That's got to be a seriously panicked sell or someone who just needs the cash. Creates a great opportunity to buy at ridiculously low prices. I just wish I had some spare cash or I'd be adding. It is frustrating when there is little or no news forthcoming but that's the cycle we're currently in. Six month sales data will be out early September that will show how close we are to the companies prediction of 'in profit by 2020'......

Thanks C7 I thought the MM's were up to their old tricks again...

Hi C7, just for the record I bought 70k shares yesterday at 12.40p and as far as I can decern that has not been declared either. Chester.

Hi Jurado.. This RNS is a good positive start to the news flow we desire. I realise that the year 2020 seems quite far off but at some point the potential worth of this company will hit the mainstream and then larger investors will want a piece of the pie. I started here at 22p thinking that was cheap so looking forward to this rising steadily towards your 30p plus. It's definitely a buy and hold all the way to profitability for me. ATB Chester

Totally agree Sandhopper my thoughts are that TRX plus Cellright put us right up in the front line of this emerging bio-medical frontier. As I have said before we have the products that the doctors and surgeons are crying out for because they are easier to apply, quicker to heal and therefore save time and money. The growth of this market could be amazing over the next five to ten years. Patience it is for the moment but a couple of good news RNS's will start to push up the SP. Chester

This is definitely a share where we need to have some patience because the price will only move on news of continued sales growth. But it would be nice to have an update especially on the progress of the newer products, developments coming out of the lab and where we are with approvals ect.. Any comments back would really liven up this BB. All the best Chester

Let's presume for a minute that there is confidence Scancell's technology is tempting one of the big pharma companies at this stage of develpment. How do you think the conversation goes. Big Pharma... "Well your technology is not proven yet but we feel we could take a punt and offer you £30M" Scancell, "Well there's the door" That's what I call a BOD doing their job and protecting us shareholders. What exactly do you want the BOD to do??

Really happy with the progress of the company and the new level of the SP at this stage. Just like to know if anyone is going to the AGM in Leeds next week and can report back, would be very interested to hear how the BOD feel about future sales growth. I've seen the published sales estimates and there is quite a steep climb in turnover from now to 2021. It will be good to have a first hand account as to how confident they are that those targets are achievable or even bettered. There could possibly be some news due about the European joint venture plus approval. Chester

I have just set my alarm for 7.00am. Looking forward to and anticipating some good results on the sales of Dermapure. Very interested in how Cellright has progressed since the takeover. My main hope is that the profits have increased sufficiently to slow down the reduction rate of the cash at the bank. These details are not the be all and end all but will give a clear indicator as to how well the new larger company is functioning. ATB Chester

Thank you Sandhopper. I owe everyone an apology because I've calculated the figures based on a full year of Cellright Sales. But it will only be 5 months maximum which will bring the groups total 2017 down to around £7.5 / £8 million, given that all sales are equal to 2016 plus growth. Therefore I will curb my enthusiasm and quietly await the facts on the 19th. I hope I have not inadvertently influenced anybody as it was not my intention. ATB Chester

I am definitely an optimism with Tissue Regenix, they do say though, a Pessimist is either Right or pleasantly surprised ..... Taking on both the previous posts regarding cash burn and profitability, I've re-read the Hardman report and the Cellright financials at the point of acquisition and these are the predictions from both. Dermapure Turnover � 3.5 m with an estimated profit generation of � 2.20 m GBM-V Turnover � 1.2 m with profit of � 0.72 m Cellright Turnover � 6.5 m with profit of � 3.90 m These are all projected earnings based on 2016 achieved figures and stated projected growth in 2017. So we have the potential of a group turnover � 11.20 m profit � 6.82 m If achieved will mean the cash in the bank could be at least �5 or �6 m or above. Its going to be very interesting to see the actual figures in just 12 days time. If those estimated numbers are somewhere near correct I would expect the SP to rise well above 10p and I would not be surprised if it went higher. These are all figures that are in the published reports, but do your own research. Ever the Optimist, Chester

Absolutely, I've just bought 25k at vertually 8.9p because I believe that this company is going places. Plus they have said that they aim to be in profit by 2020. I'm looking for decent dividends as they grow.

I said we may see the start of some good news and the Cellright multi year deal is not good news its excellent news. It gives me even more confidence that the TRX group is offering outstanding and needed products in a competitive US market. Also, I just cannot see the unaudited accounts to be announced on the 19th to be anything less than, turnover up, profits up and still healthy cash in the bank. I am convinced that the time to top up in nigh. As always Do your own research.

Lets hope that this is the beginning of some kind of news flow, the wording is very positive and upbeat. Without saying that turnover is still growing it does hint at the fact that more Clinicians are asking and taking TRX products. The agreement with ARMS Medical is an excellent tactical deal that allows the US sales force to be more focused on the wound care market, which I am presuming is many times bigger than the sector to be pursued by ARMS. The next few weeks running up to the 19th are going to be very interesting and the share price may well rise towards that date. If the unaudited preliminary results show strong sales growth and decreasing cash burn it would not surprise me if we are back around 14p. I am optimistic with TRX because their product range is what hospitals, doctors and sugeons actually need. All my own opinion please do your own reasearch. ATB Chester..

So Positive RNS and no comments or positive buys, the world of RENE is upside down !!!!!

Wishing all TRX shareholders, wether you are a long term holder like me or recent new comer, a very healthy and profitable 2018. Chester